Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +63.03%
#3 MetaDAO MetaDAO +28.63%
#4 Pons Pons +28.12%
#5 Rain Rain +23.09%
#6 Bedrock Bedrock +20.96%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +17.95%
#8 Ontology Gas Ontology Gas +17.34%
#9 Prom Prom +16.62%
#10 Humanity Humanity +14.86%
Coin of the day
QuantixAI QuantixAI
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
शेयरों में रैंक #20198
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
शेयर मूल्य
$10.25
अंतिम समन्वयन: 2024-02-22
मार्केट कैप
$137.83M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
CN
व्यापार Gracell Biotechnologies Inc. (GRCL)

श्रेणी

Healthcare
Gracell Biotechnologies Inc. (GRCL) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $10.24 (2024-02-01 को)

दिन का सबसे निम्न समापन मूल्य: $22.88 (2021-01-01 को)
Gracell Biotechnologies Inc. के स्टॉक मूल्य का इतिहास 2021 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
वर्ष प्रदर्शन
2024 60.59%
2023 155.25%
2022 -61.61%
2021 0.00%
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
कंपनी स्टॉक मूल्य परिवर्तन 1व% देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH